Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement